HealthUnited KingdomJun 28, 2026

Thalia Therapeutics raises $3.3M (United Kingdom, Jun 2026)

$3.3M
€3.1 Million
Browse investors in United Kingdom →
Generated social card
Thalia Therapeutics social card
Headline

Thalia Therapeutics Secures €3.1 Million and Acquires Sanmi - n24.com.tr

About

Thalia Therapeutics is a UK-based biotechnology company specializing in RNA-based medical solutions. The company has raised €3.1 million to accelerate its clinical-stage oncology and RNA-based pipeline, including the acquisition of Sanmirna Therapeutics, which brings a microRNA therapeutic candidate into its portfolio.

Article summary

Thalia Therapeutics Secures €3.1 Million and Acquires Sanmi  n24.com.tr

Founder
Dr. David Solomon
CEO
Investors · 1
Premier MitonLead
FUND
Related rounds
Jun 27, 2026DeepTech Catalyst Quantum$61KGrantUnited Kingdom
Jun 24, 2026Equipal$20.0M—United Kingdom
Jun 23, 2026Astral Systems$27.6MSeries AUnited Kingdom
Jun 23, 2026TRIMTECH Therapeutics$44.1MSeedUnited Kingdom
Thalia Therapeutics raises $3.3M (United Kingdom, June 2026) | Datapile